{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:23:57Z","timestamp":1777883037208,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["NH RI-110A1-CACO-13212102"],"award-info":[{"award-number":["NH RI-110A1-CACO-13212102"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST109-2321-8-006-011-"],"award-info":[{"award-number":["MOST109-2321-8-006-011-"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Executive Yuan Republic of China Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW110-TDU-B-212-010001"],"award-info":[{"award-number":["MOHW110-TDU-B-212-010001"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Executive Yuan Republic of China Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW110-TDU-B-212-144026"],"award-info":[{"award-number":["MOHW110-TDU-B-212-144026"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejca.2021.01.045","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T11:08:58Z","timestamp":1616065738000},"page":"48-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Intraperitoneal nivolumab in a patient with pancreatic cancer and refractory malignant ascites"],"prefix":"10.1016","volume":"148","author":[{"given":"Sing-Ting","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Fang","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Jen","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7739-4077","authenticated-orcid":false,"given":"Li-Yuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.01.045_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ejca.2005.11.018","article-title":"Malignant ascites: systematic review and guideline for treatment","volume":"42","author":"Becker","year":"2006","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.01.045_bib2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.immuni.2009.03.014","article-title":"Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens","volume":"30","author":"Rangel-Moreno","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2021.01.045_bib3","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10637-016-0369-0","article-title":"Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites","volume":"34","author":"Takahara","year":"2016","journal-title":"Invest New Drugs"},{"issue":"S4","key":"10.1016\/j.ejca.2021.01.045_bib4","doi-asserted-by":"crossref","first-page":"S1195","DOI":"10.1016\/j.annonc.2020.08.2300","volume":"31","author":"Renouf","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.01.045_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ar.1092410204","article-title":"Cellular composition of milky spots in the human greater omentum: an immunochemical and ultrastructural study","volume":"241","author":"Krist","year":"1995","journal-title":"Anat Rec"},{"key":"10.1016\/j.ejca.2021.01.045_bib6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/BF01221190","article-title":"Role of milky spots as selective implantation sites for malignant cells in peritoneal dissemination in mice","volume":"122","author":"Tsujimoto","year":"1996","journal-title":"J Canc Res Clin Oncol"},{"key":"10.1016\/j.ejca.2021.01.045_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.canlet.2007.10.038","article-title":"Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells","volume":"260","author":"Ikehara","year":"2008","journal-title":"Canc Lett"},{"key":"10.1016\/j.ejca.2021.01.045_bib8","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2021.01.045_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas","year":"2017","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2021.01.045_bib10","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1590\/s0102-865020170120000002","article-title":"Effects of nivolumab in peritoneal carcinamatosis of malign melanoma in mouse model","volume":"32","author":"Duzgun","year":"2017","journal-title":"Acta Cir Bras"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:31:47Z","timestamp":1777599107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921000812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":10,"alternative-id":["S0959804921000812"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.045","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal nivolumab in a patient with pancreatic cancer and refractory malignant ascites","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}